Beovu FDA Approval History
Last updated by Judith Stewart, BPharm on June 2, 2022.
FDA Approved: Yes (First approved October 7, 2019)
Brand name: Beovu
Generic name: brolucizumab-dbll
Dosage form: Injection
Company: Novartis Pharmaceuticals Corporation
Treatment for: Macular Degeneration, Diabetic Macular Edema
Beovu (brolucizumab-dbll) is a human vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME).
- In AMD, Beovu works by inhibiting VEGF to suppress the growth of abnormal blood vessels under the macula and reduce the potential for vision loss caused by fluid leakage into the retina.
- In DME, Beovu works by inhibiting VEGF (which is elevated when small blood vessels are damaged due to consistently high blood sugar levels associated with diabetes) to suppress the growth of abnormal, leaky blood vessels that cause edema.
- Beovu is administered by intravitreal injection into the vitreous cavity of the eye. In AMD, the injections are given every month for the first three doses, then every 8-12 weeks. In DME, then injections are given every six weeks for the first five doses, then every 8-12 weeks.
- Common side effects include: vision blurred, cataract, conjunctival hemorrhage, vitreous floaters, and eye pain.
Development timeline for Beovu
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
